Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses - Archive ouverte HAL Access content directly
Journal Articles PPAR Research Year : 2021

Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses

(1) , (2, 1) , (3) , (1) , (4) , (1)
1
2
3
4

Abstract

According to the Center for Disease Control and Prevention (CDC), the coronavirus disease 2019, a respiratory viral illness linked to significant morbidity, mortality, production loss, and severe economic depression, was the third-largest cause of death in 2020. Respiratory viruses such as influenza, respiratory syncytial virus, SARS-CoV-2, and adenovirus, are among the most common causes of respiratory illness in humans, spreading as pandemics or epidemics throughout all continents. Nanotechnologies are particles in the nanometer range made from various compositions. They can be lipid-based, polymer-based, protein-based, or inorganic in nature, but they are all bioinspired and virus-like. In this review, we aimed to present a short review of the different nanoparticles currently studied, in particular those which led to publications in the field of respiratory viruses. We evaluated those which could be beneficial for respiratory disease-based viruses; those which already have contributed, such as lipid nanoparticles in the context of COVID-19; and those which will contribute in the future either as vaccines or antiviral drug delivery systems. We present a short assessment based on a critical selection of evidence indicating nanotechnology’s promise in the prevention and treatment of respiratory infections.
Fichier principal
Vignette du fichier
mignet-hindawi.pdf (2.04 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03423555 , version 1 (10-11-2021)

Identifiers

Cite

Mahdi Ftouh, Nesrine Kalboussi, Nabil Abid, Souad Sfar, Nathalie Mignet, et al.. Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. PPAR Research, 2021, 2021, pp.1-28. ⟨10.1155/2021/6741290⟩. ⟨hal-03423555⟩
11 View
42 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More